Port Louis

Researchers are evaluating the skin tolerance and lightening effects of a cosmetic depigmenting serum compared to a 4% hydroquinone-based cream in adults aged 18 to 65 with mild to moderate epidermal or mixed-type melasma. This randomized, double-blind trial aims to determine if the cosmetic serum can reduce melasma severity similarly or better than hydroquinone, while offering improved skin tolerability. Melasma is a chronic skin condition causing irregular brown patches on sun-exposed facial areas and is often worsened by UV exposure and hormonal changes. Participants are divided into two groups: one applying the cosmetic depigmenting serum morning and evening with a placebo cream in the evening, and the other applying a placebo serum morning and evening with a 4% hydroquinone cream in the evening. All participants use a high-protection SPF50+ sunscreen each morning during the 84-day study. Products are applied topically with consistent routines and visually matched to maintain blinding. During the study, participants visit the clinic at baseline, day 56, and day 84 for assessments including mMASI scoring by a blinded dermatologist, standardized facial photography, self-assessment questionnaires, and quality-of-life surveys. Researchers measure changes in melasma severity and skin tolerance, monitor safety through skin examinations and patient reports, and analyze pigmentation changes using advanced imaging techniques over the 12-week treatment period.